Leslie A Morrison

List of Publications by Year
in descending order

45 papers	3,493 citations	279487 23 h-index	253896 43 g-index
46 all docs	46 docs citations	46 times ranked	3985 citing authors

#	Article	IF	Citations
1	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	3.8	43
2	Health related quality of life in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.3	4
3	Systemic and CNS manifestations of inherited cerebrovascular malformations. Clinical Imaging, 2021, 75, 55-66.	0.8	6
4	Seizure Incidence Rates in Children and Adults With Familial Cerebral Cavernous Malformations. Neurology, 2021, 97, e1210-e1216.	1.5	7
5	Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation. Molecular Genetics & Genomic Medicine, 2021, 9, e1794.	0.6	2
6	Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial. Translational Stroke Research, 2020, 11, 319-321.	2.3	18
7	Vertebral Intraosseous Vascular Malformations in a Familial Cerebral Cavernous Malformation Population: Prevalence, Histologic Features, and Associations With CNS Disease. American Journal of Roentgenology, 2020, 214, 428-436.	1.0	7
8	High Prevalence of Spinal Cord Cavernous Malformations in the Familial Cerebral Cavernous Malformations Type 1 Cohort. American Journal of Neuroradiology, 2020, 41, 1126-1130.	1.2	12
9	Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nature Communications, 2020, 11, 2659.	5.8	27
10	Cutaneous findings of familial cerebral cavernous malformation syndrome due to the common Hispanic mutation. American Journal of Medical Genetics, Part A, 2020, 182, 1066-1072.	0.7	9
11	Subjective Cognitive Concerns and Attitudes toward Genetic Testing Are Associated with Depressive Symptoms and Quality of Life after Genetic Testing for the Cerebral Cavernous Malformation Common Hispanic Mutation (CCM1). Journal of Behavioral and Brain Science, 2020, 10, 118-127.	0.2	0
12	Familial Cerebral Cavernous Malformations. Stroke, 2019, 50, 1294-1301.	1.0	92
13	Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Science Translational Medicine, 2019, 11, .	5.8	51
14	Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery, 2019, 85, 843-853.	0.6	58
15	Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease. JAMA Neurology, 2019, 76, 492.	4.5	36
16	Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery, 2019, 84, 954-964.	0.6	34
17	Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature, 2017, 545, 305-310.	13.7	247
18	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 2017, 58, 34-39.	0.8	56

#	Article	IF	Citations
19	Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations. Neuroradiology, 2017, 59, 685-690.	1.1	8
20	Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery, 2017, 80, 665-680.	0.6	334
21	Familial Cerebral Cavernous Malformations Are Associated with Adrenal Calcifications on CT Scans: An Imaging Biomarker for a Hereditary Cerebrovascular Condition. Radiology, 2017, 284, 443-450.	3.6	8
22	Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radical Biology and Medicine, 2016, 92, 100-109.	1.3	47
23	Factors Affecting Eyelid Crease Formation Before and After Silicone Frontalis Suspension for Adult-Onset Myogenic Ptosis. Ophthalmic Plastic and Reconstructive Surgery, 2015, 31, 227-232.	0.4	5
24	Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. Journal of Medical Imaging and Radiation Oncology, 2015, 59, 134-136.	0.9	13
25	Hip flexion weakness is associated with impaired mobility in oculopharyngeal muscular dystrophy: A retrospective study with implications for trial design. Neuromuscular Disorders, 2015, 25, 238-246.	0.3	12
26	Muscle Weakness and Speech in Oculopharyngeal Muscular Dystrophy. Journal of Speech, Language, and Hearing Research, 2015, 58, 1-12.	0.7	32
27	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology, 2015, 84, 1369-1378.	1.5	88
28	Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology, 2015, 85, 1432-1433.	1.5	3
29	Association of Cardiovascular Risk Factors with Disease Severity in Cerebral Cavernous Malformation Type 1 Subjects with the Common Hispanic Mutation. Cerebrovascular Diseases, 2014, 37, 57-63.	0.8	38
30	Polymorphisms in Inflammatory and Immune Response Genes Associated with Cerebral Cavernous Malformation Type 1 Severity. Cerebrovascular Diseases, 2014, 38, 433-440.	0.8	57
31	Dynamic Contrast-Enhanced MRI Evaluation of Cerebral Cavernous Malformations. Translational Stroke Research, 2013, 4, 500-506.	2.3	28
32	Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. The Journal of Rare Disorders, 2013, 1, 5.	1.5	21
33	Primary bilateral silicone frontalis suspension for good levator function ptosis in oculopharyngeal muscular dystrophy. British Journal of Ophthalmology, 2012, 96, 841-845.	2.1	18
34	ATP1A3 mutations in infants: a new rapidâ€onset dystoniaâ€“Parkinsonism phenotype characterized by motor delay and ataxia. Developmental Medicine and Child Neurology, 2012, 54, 1065-1067.	1.1	78
35	Consensus Statement on Standard of Care for Congenital Myopathies. Journal of Child Neurology, 2012, 27, 363-382.	0.7	147
36	Dystrophinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 101, 11-39.	1.0	17

#	Article	IF	Citations
37	Swallow Characteristics in Patients With Oculopharyngeal Muscular Dystrophy. Journal of Speech, Language, and Hearing Research, 2010, 53, 1567-1578.	0.7	32
38	Clinical Characterization and Blepharoptosis Surgery Outcomes in Hispanic New Mexicans With Oculopharyngeal Muscular Dystrophy. Ophthalmic Plastic and Reconstructive Surgery, 2009, 25, 103-108.	0.4	13
39	Unraveling RYR1 mutations and muscle biopsies. Neurology, 2008, 70, 99-100.	1.5	4
40	Hemorrhage From Cavernous Malformations of the Brain. Stroke, 2008, 39, 3222-3230.	1.0	230
41	Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology, 2007, 22, 1027-1049.	0.7	754
42	Use of tissue water as a concentration reference for proton spectroscopic imaging. Magnetic Resonance in Medicine, 2006, 55, 1219-1226.	1.9	430
43	A Founder Mutation as a Cause of Cerebral Cavernous Malformation in Hispanic Americans. New England Journal of Medicine, 1996, 334, 946-951.	13.9	257
44	A Locus for Cerebral Cavernous Malformations Maps to Chromosome 7q in Two Families. Genomics, 1995, 28, 311-314.	1.3	110
45	Familial cavernous malformations: a historical survey. , 0, , 15-20.		0